S&P: BioReliance unaffected

Standard & Poor's said its B+ and stable ratings on BioReliance Corp. are unaffected following the company's agreement to be acquired by Sigma-Aldrich in an all-cash transaction valued at roughly $350 million.

BioReliance's existing loans are expected to be repaid as part of the transaction.

S&P said it plans to withdraw its issue level and corporate credit ratings on BioReliance upon completion of the acquisition.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.